StreetAlpha.app
Home › Stocks › IMDX

Insight Molecular Diagnostics Inc. (IMDX)

$1.78
▼ −4.30%
LAST CLOSE · NOV 17

iMDx develops molecular diagnostic tests for transplanted organ rejection and sells them to hospitals, transplant centers and labs. It last closed at $1.78 on Nov 17, down 4.30% on the day. IMDX last reported earnings on Mon, Nov 16, 2026.

AI Auto Pilots
Is IMDX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.0M
−55.3% vs a year ago
Net income
−$42.1M
−2137.3% margin
EPS (diluted)
−$1.27
Free cash flow
−$32.6M
−1655.5% margin
Valuation
Market cap
$58.3M
32.8M shares
P/E
–
No P/E while losing money
Price to sales
29.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$11.0M
At Sep 30
Shareholder equity
−$24.2M
Shares outstanding
32.8M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.2M$2.2MFY2021FY2022: $958K$958KFY2022FY2023: $1.5M$1.5MFY2023FY2024: $1.9M$1.9MFY2024FY2025: $4.1M$4.1MFY2025

From IMDX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · After the close (AMC)
Reported EPS
-$0.23
vs -$0.23 est. · inline
Year-ago EPS
-$0.23
Same quarter last year
Options-implied move
±75.9%
Priced in before that report
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IMDX in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 349.4% upside

Based on 1 analyst who set a price target on IMDX in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.78.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.78
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
LUCID CAPITAL MARKETSInitiated
Aug 24Buy$8
NeedhamReiterated
Aug 18Buy$9
DateFirmActionRatingPrice target
Aug 24LUCID CAPITAL MARKETSInitiatedBuy$8
Aug 18NeedhamReiteratedBuy$9
Loading…

Technical Analysis

IMDX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 48% below its 20 day and 80% below its 50 day average. It is 152% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the Pivot at $1.74, and the nearest resistance the Pivot R1 at $1.84.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 14.6%/day
Key levels
$7.5652 week high+324.7%
$4.48200 day average+151.7%
$3.92100 day average+120.2%
$3.25Swing high (Oct 27)+82.6%
$3.2050 day average+79.8%
$2.6420 day average+48.3%
$1.84Pivot R1+3.4%
$1.78Last close
$1.74Pivot−2.2%
$1.68Pivot S1−5.6%
$1.6452 week low−7.9%
Indicators
RSI (14)20.69Oversold below 30Oversold
MACD-0.35Below its signal lineBearish
Stochastic5.0Near the bottom of its rangeOversold
ADX (14)40.1Strong downtrend
Williams %R-91.0Oversold below −80, overbought above −20Oversold
CCI (20)-185.6Oversold below −100, overbought above 100Oversold
Rate of change−35.0%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 14.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IMDX

What happened before

See how IMDX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IMDX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IMDX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IMDX in the last 90 days.

Loading…

See today’s whale options flow across the market →

IMDX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲25 buying vs 16 selling
  • ●Held by funds +0.2 pts
  • ▲Funds holding +4
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4440+10.0%
In funds' top 1012−50.0%
Held by funds56.6%56.4%+0.3 pts
New / increased13 / 1211 / 10+19.0%
Reduced / sold out8 / 88 / 13−23.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IMDX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMDX is in one of them and how their past IMDX trades turned out.

IMDX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IMDX in an article yet. Here's the latest on the wider market.

About Insight Molecular Diagnostics

iMDx is a diagnostics company based in Nashville, Tennessee. Its main focus is molecular tests that help monitor whether a transplanted organ is being rejected, sold under the GraftAssure name. The test kits are meant for hospitals, transplant centers and labs to run in their own facilities, and research kits are offered to research laboratories. The company also runs a clinical lab in Franklin, Tennessee, and provides assay development and testing services to life sciences and biotechnology companies.

Headquarters
Nashville, TN